Highest-materiality recent filing
Nuwellis announces 1-for-35 reverse stock split effective June 25, 2026
Board approved 1-for-35 reverse stock split on June 16, 2026, following shareholder authorization obtained on August 4, 2025.
Nuwellis appoints Michael McCormick as CEO effective June 30, 2026; Erb remains Chairman
John Erb resigns as President and CEO effective June 30, 2026; will continue as Chairman of the Board.
Nuwellis closes $6.0M public offering of shares and warrants
Gross proceeds of ~$6.0M from 1,903,338 common shares and pre-funded warrants with Series C/D warrants.
Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M
Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).
Nuwellis annual meeting elects two Class I directors, ratifies auditor
Marty J. Emerson elected with 397,057 FOR vs 23,144 withheld; 657,819 broker non-votes.
Nuwellis settles E.F. Hutton lawsuit for $204K; mutual release, dismissal with prejudice
Settlement Agreement executed April 24, 2026; payment of $204,000 within five days.
Nuwellis amends 8-K to include former directors' response letters; company disputes statements
Mika Grasso and Katharyn Field resigned from Board effective March 26, 2026.
Two Nuwellis directors resign over information-access disagreements; board reduced to five
Mika Grasso and Katharyn Field resigned effective March 26, 2026, citing alleged failures to provide timely information.
Nuwellis closes acquisition of Rendiatech, automated kidney monitoring tech
Closed acquisition of Rendiatech, Inc., an Israeli developer of automated kidney function monitoring technology.
Nuwellis Q4 revenue +4% to $2.4M; full year -5%; acquires Rendiatech
Q4 2025 revenue $2.4M (+4% YoY, +9% sequential); gross margin 68.2% vs 58.4% prior year.
Nuwellis appoints two directors; E.F. Hutton files breach-of-contract lawsuit
Board expanded from 5 to 7; appointed Martin Emerson (Monteris Medical CEO) and David McDonald (Lake Street Vice Chairman) as Class I directors.
Gross proceeds ~$5M from private placement (994,537 shares/pre-funded + 1,989,074 warrants) and warrant inducement (623,585 shares exercised, 1,247,170 new warrants).
Nuwellis appoints two new directors; three resign, board shrinks from 6 to 5
Three directors (Dave McDonald, Mike McCormick, Maria Costanzo) resigned effective Jan 21, 2026; resignations not due to any disagreement.
Nuwellis Q3 revenue $2.2M, down 6% YoY, up 29% sequentially; operating loss widens to $2.7M
Total revenue $2.2M, down 6% YoY but up 29% sequentially; pro-forma revenue grew ~7% YoY excluding one-time items.
Nuwellis CFO Robert Scott resigns; CEO John Erb appointed interim CFO
CFO Robert B. Scott resigns; last day on or about Oct 24, 2025; not due to any disagreement.
Nuwellis announces ULTRA-Peds registry study findings on Aquadex System in pediatric AKI
ULTRA-Peds registry is multi-center observational study of real-world Aquadex System use.
US Patent No. 12,415,021 issued September 16, 2025, for hemolysis sensors with extracorporeal blood filtration systems.
NIH awards $3M grant to Nuwellis partner KBT for pediatric CRRT device Vivian
NIH grant to Koronis Biomedical Technologies supports Nuwellis' pediatric CRRT device Vivian for patients under 20 kg.
Nuwellis enters ATM offering to sell up to $4.65M of common stock
Entered At The Market Offering Agreement with Ladenburg Thalmann to sell common stock up to $4,650,000.
Nuwellis gets FDA 510(k) clearance for new catheter size
FDA 510(k) clearance received for new size of Nuwellis' Dual Lumen Extended Length Catheter (dELC) on August 21, 2025.
Nuwellis enters non-binding LOI to acquire Rendiatech, an Israeli renal monitoring firm
Rendiatech specializes in real-time urine flow and acute kidney injury monitoring technologies.
Nuwellis Q2 2025 revenue down 23% YoY to $1.7M; net loss widens to $12.6M
Revenue $1.7M vs $2.2M in Q2 2024; decline due to sterilization vendor backorder.
Nuwellis shareholders approve reverse stock split and increase in authorized shares
Shareholders approved a reverse stock split of 1:5 to 1:70, with board discretion to implement within 12 months to regain Nasdaq listing compliance.
Nuwellis regains compliance with Nasdaq minimum bid price requirement; delisting avoided
On July 22, 2025, Nasdaq notified Nuwellis that its bid price deficiency was cured and listing continues.
Nuwellis appoints John L. Erb as CEO and President, approves 1-for-42 reverse stock split
John L. Erb appointed President and CEO effective June 27, 2025, with annual base salary of $431,097 and stock option grant of 115,329 shares vesting monthly.
Nuwellis receives Nasdaq delisting notice for bid price below $1.00; plans reverse split and hearing
Received Nasdaq Deficiency Notice on June 18, 2025 for failure to meet $1.00 minimum bid price requirement.
Nuwellis exchanges CEO's Series F preferred for new Series F-1 with 19.99% conversion cap
CEO John L. Erb exchanged 100 shares of Series F Preferred for 100 shares of newly designated Series F-1 Convertible Preferred on June 9, 2025.
Reverse split approved with 1,792,386 votes for, 386,100 against; Board may implement within 12 months.
Nuwellis Q1 2025 revenue $1.9M (+3% YoY); net loss narrows to $3.0M
Revenue $1.9M (+3% YoY); consumables utilization +4%; pediatric revenue +38%.
Nuwellis enters 3-year supply agreement with Kluge Design for Aquadex manufacturing
KDI exclusively manufactures Aquadex Blood Circuit, dELC Catheter, SmartFlow Console globally; Nuwellis retains IP.
Nuwellis posts updated corporate presentation; no financial details disclosed
Presentation posted April 3, 2025 on Nuwellis investor relations website.
Nuwellis Q4 revenue $2.3M (-9% YoY); net loss narrows to $1.5M from $7.9M
Q4 revenue $2.3M, down 9% YoY; consumables utilization +21%, critical care revenue +35%.
Nuwellis CEO Nestor Jaramillo Jr. retires; Chairman John Erb named interim CEO
Nestor Jaramillo Jr. retired as President, CEO, and director effective Feb 18, 2025; retirement was not due to any dispute.
Nuwellis regains Nasdaq compliance with bid price and equity listing rules
Received Nasdaq confirmation of compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)(1)).
Nuwellis voluntarily recalls AquaFlexFlow UF 500 Plus blood circuits over mismatch alarms
Recall of specific lots due to 'Ultrafiltrate Weight Mismatch' alarms; may cause excess fluid removal leading to acute volume depletion.
Nuwellis Q3 revenue $2.4M, net income $2.4M; CMS reimbursement up 297%
Revenue $2.4M, down 2% YoY; pediatrics revenue grew 28% YoY.
Nuwellis raises $5.1M via warrant inducement; issues new warrants for 3.7M shares
Total gross proceeds of $5.1M, including $3.8M from immediate exercise of 1.8M existing warrants at $2.10 and $1.3M from recent exercises at original terms.
Nuwellis reports preliminary Q3 revenue ~$2.4M, gross margin 70%, cash $1.9M
Revenue of approximately $2.4 million; pediatric category grew 28% YoY.
Nuwellis terminates distribution deal with SeaStar Medical, receives $900k settlement
SeaStar pays Nuwellis $900k in three installments: $500k (less offsets) by Oct 22, $250k by Nov 30, $150k by Dec 31, 2024.
Nuwellis prices $916,000 registered direct offering with warrants at $1.72 strike
Gross proceeds ~$916k from sale of 496,901 shares at $1.845/share and warrants for 496,901 shares.
Nuwellis and DaVita mutually terminate Supply and Collaboration Agreement effective Aug 21, 2024
Supply and Collaboration Agreement with DaVita terminated by mutual agreement effective August 21, 2024.
Nuwellis Q2 revenue up 6% to $2.2M; gross margin expands to 67.2%
Revenue $2.2M (+6% YoY); Critical Care revenue up 28%, Heart Failure consumables utilization up 35%.
Nuwellis granted continued Nasdaq listing subject to Q3 2024 10-Q evidencing equity compliance
Nasdaq panel granted continued listing on August 8, 2024, following July 23 hearing.
Nuwellis prices $2M registered direct offering of 469,340 shares at $4.24 plus warrants
Gross proceeds ~$2.0M; net proceeds ~$1.6M after fees.
Nuwellis adds off-label use risk factor and updates investor presentation
Filed 8-K/A to replace corporate presentation; updated version posted to investor website.
Nuwellis adds risk factor on off-label Aquadex use in neonates under 20 kg
Aquadex System cleared only for patients ≥20 kg, but is being modified for neonates/kidney failure infants.
Nuwellis announces first commercial sale of QUELIMMUNE therapy for pediatric AKI/sepsis
First commercial sale of QUELIMMUNE to Cincinnati Children's Hospital for pediatric AKI/sepsis patients.
Nuwellis terminates ATM equity offering agreement with Ladenburg Thalmann effective July 9, 2024
Termination notice delivered to Ladenburg Thalmann & Co. Inc. on July 1, 2024; effective July 9, 2024.
Nuwellis (NUWE) to effect 1-for-35 reverse stock split on June 27, 2024
Nuwellis (NUWE) approved 1-for-35 reverse stock split effective 5:00 pm ET June 27, 2024.
Nasdaq notified Nuwellis on June 5, 2024 of delisting due to continued non-compliance with $1.00 minimum bid price requirement.
Effective as of June 30, 2026, the Board appointed Michael McCormick as the Company’s Chief Executive Officer and President and member of the Company’s board of directors.
On June 16, 2026, Nuwellis, Inc. (the “Company” ) announced that John L. Erb resigned from the Company, effective June 30, 2026 (“ Resignation Date ”).
Effective as of June 30, 2026, the Board appointed Michael McCormick as the Company’s Chief Executive Officer and President and member of the Company’s board of directors.
Nestor Jaramillo, Jr. is retiring from the Company, effective February 18, 2025
the Board appointed John L. Erb as the Company’s Interim Chief Executive Officer and President.
the appointment of Archelle Georgiou (Feldshon) , M.D. to its Board
the appointment of David McDonald to its Board
Robert B. Scott will be appointed as Chief Financial Officer of Nuwellis, Inc.
On August 4, 2023, Lynn Blake notified Nuwellis, Inc., a Delaware corporation (the “ Company ”) of her decision to resign as the Chief Financial Officer of the Company.
The Company intends to appoint Rob Scott, the Company’s current Senior Finance Director, as its new Chief Financial Officer, effective September 2, 2023.
On May 30, 2023, the Board of Directors (the " Board ") of Nuwellis, Inc., a Delaware corporation (the " Company ") approved, effective as of June 1, 2023, the appointment of Michael McCormick to fill a vacancy in the Board.
On January 16, 2023, Mr. Steve Brandt provided notice of his resignation from the Board of Directors (the “Board”) of Nuwellis, Inc. (the “Company”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material